Abnormal neovascular tissue (targeted via photoactivation-induced cytotoxicity)

Abnormal neovascular tissue via photoactivation-induced cytotoxicity" does not refer to a specific molecular target such as a receptor, enzyme, or transporter. Instead, it describes the **therapeutic strategy** used in photodynamic therapy for conditions like age-related macular degeneration and other diseases characterized by pathological angiogenesis. In this approach, drugs known as photosensitizers—such as verteporfin or methotrexate—are administered and accumulate preferentially in abnormal new blood vessels. Upon activation by light at specific wavelengths, these agents generate reactive oxygen species that induce localized cytotoxicity and vessel closure. This "target" is not a molecule but rather **pathological tissue** defined by its function and disease context. The actual molecular targets involved may include cellular components within proliferating endothelial cells or factors like VEGF that drive angiogenesis; however, the direct action is on the abnormal vasculature itself through non-specific oxidative damage following photoactivation. Because this entry refers to an anatomical/pathophysiological process rather than a discrete molecular entity or protein target classically recognized in pharmacology databases—and because it lacks specificity regarding any single molecule—it should be flagged as incorrect for structured target mapping purposes.

Other names

Neovascular tissuePathological neovasculatureChoroidal neovascularization (context-dependent)

Photoactivation of a photosensitizer leads to production of reactive oxygen species, causing selective cytotoxicity and destruction of abnormal blood vessels